Eton Pharmaceuticals, Inc. completed its acquisition of Increlex on 2024-12-20, according to the Form 8-K/A Eton Pharmaceuticals, Inc. filed with the SEC on 2025-11-18. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Eton Pharmaceuticals, Inc. |
|---|---|
| Acquired | Increlex |
| Completed | 2024-12-20 |
| Reported by | Eton Pharmaceuticals, Inc. (ETON), the buyer |
| Filing | Form 8-K/A, filed 2025-11-18 |
Want the whole picture on Eton Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eton Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eton Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On December 20, 2024, Eton Pharmaceutical, Inc. (the "Company'') filed a Current Report on Form 8-K reporting that on December 1 9, 2024, the Company completed its purchase (the "Acquisition") of Increlex ("Increlex") from Ipsen S.A. ("Ipsen").
More from the filing
On March 7, 2025, the Company filed Amendment No. 1 to Form 8-K ("Amendment No. 1") amending the Form 8-K filed on December 20, 2024 (the "Original Report").
Amendment No. 1 was being filed to provide the status of filing the financial statements relating to the Increlex as required by Item 9.01 of Form 8-K. Amendment No. 1 amended Item 2.01 and included additional information under Item 8.01 and no changes have been made to the Original Report.
This Current Report on Form 8-K/A amends the original Form 8-K filed on December 20, 2024 to provide the historical financial statements of the Acquisition required under Item 9.0l(a) of Form 8-K and the pro forma financial information required under Item 9.0l(b) of Form 8-K. Except as set forth herein, this amendment does not amend, modify or update the disclosure contained in the original Form 8-K (including the exhibits thereto).
Quoted from Eton Pharmaceuticals, Inc.'s Form 8-K/A.
This is the only completed acquisition Eton Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Eton Pharmaceuticals, Inc.Look up Eton Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.